US 12,344,896 B2
Single nucleotide polymorphism marker for precocious puberty diagnosis or treatment prognosis prediction, and use thereof
Jin Soon Hwang, Seoul (KR); Seon Yong Jeong, Yongin-si (KR); Hae Sang Lee, Yongin-si (KR); and Eun Young Kim, Seoul (KR)
Assigned to AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, Suwon-si (KR)
Filed by AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, Suwon-si (KR)
Filed on Aug. 6, 2021, as Appl. No. 17/395,769.
Application 17/395,769 is a continuation in part of application No. PCT/KR2019/018703, filed on Dec. 30, 2019.
Claims priority of application No. 10-2019-0014993 (KR), filed on Feb. 8, 2019; and application No. 10-2019-0046714 (KR), filed on Apr. 22, 2019.
Prior Publication US 2021/0395826 A1, Dec. 23, 2021
Int. Cl. C12Q 1/6883 (2018.01)
CPC C12Q 1/6883 (2013.01) [C12Q 2600/156 (2013.01)] 4 Claims
 
1. A method for preventing or treating precocious puberty in a human subject comprising:
(a) obtaining a nucleic acid sample from the human subject;
(b) detecting, in the nucleic acid sample, presence of one or two C alleles at SNP rs10900855 and one or two G alleles at SNP rs6806402;
(c) identifying the human subject as having an increased risk of developing precocious puberty; and
(d) administering a pharmaceutical composition including a therapeutically effective amount of a gonadotropin-releasing hormone agonist (GnRHa) to the human subject.